STRUCTURE THERAPEUTICS INC (GPCR)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$19.08-6.29%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · GPCR
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Recent and Upcoming Milestones Aleniglipron – Oral Small Molecule Selective Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist for Chronic Weight Management The Company announced that the first patient…
Stated in 2 of 2 supplied quarters. Management reported: “Recent and Upcoming Milestones Aleniglipron – Oral Small Molecule Selective Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist for Chronic Weight Management The Company announced that the first patients have been dosed in the Phase 3 ACCOMPLISH program, which includes two clinical trials evaluating aleniglipron, a once-daily oral small molecule GLP-1 receptor agonist.” “ACCOMPLISH-1 (NCT07654361) is enrolling up to 3,600 adults living with obesity or overweight with at least one weight-related comorbidity, while ACCOMPLISH-2 (NCT07654374) is enrolling up to 1,100 adults living with obesity or overweight and type 2 diabetes mellitus (T2DM).”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Recent and Upcoming Milestones Aleniglipron – Oral Small Molecule Selective Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist for Chronic Weight Management The Company announced that the first patient…”
“The Company anticipates initiating the Phase 3 program in Q3 2026.”
Initial data, along with initiation of a multiple ascending dose (MAD) clinical trial, remain on track for Q3 2026.
Stated in 2 of 2 supplied quarters. Management reported: “Initial data, along with initiation of a multiple ascending dose (MAD) clinical trial, remain on track for Q3 2026.” “In the SAD trial, ACCG-2671 demonstrated a long half-life of approximately 6 days supporting potential once-weekly dosing, with no serious adverse events (SAEs) or events of liver enzyme elevations.”
“Initial data, along with initiation of a multiple ascending dose (MAD) clinical trial, remain on track for Q3 2026.”
“ACCG-2671 is being evaluated in an ongoing single ascending dose (SAD) study to measure safety, tolerability, pharmacokinetics, and food-effect of single ascending doses in healthy adult participants…”
Research and Development (R&D) Expenses: R&D expenses for the second quarter of 2026 were $100.1 million, as compared to $54.7 million for the same period in 2025.
Stated in 2 of 2 supplied quarters. Management reported: “The Company expects its current cash, cash equivalents and short-term investments to fund projected operations and key clinical milestones through the end of 2028, including costs related to the ongoing aleniglipron ACCESS OLE, ACCESS II extension clinical trial, the supplementary clinical trials, and Phase 3 registrational program in chronic weight management, but excludes additional costs related to pre-commercialization activities including commercial manufacturing.” “Research and Development (R&D) Expenses: R&D expenses for the second quarter of 2026 were $100.1 million, as compared to $54.7 million for the same period in 2025.”
“Research and Development (R&D) Expenses: R&D expenses for the second quarter of 2026 were $100.1 million, as compared to $54.7 million for the same period in 2025.”
“The Company expects its current cash, cash equivalents and short-term investments to fund projected operations and key clinical milestones through the end of 2028.”
Mr. Berrios brings more than 25 years of commercial leadership experience across the biopharmaceutical industry, with expertise spanning commercial strategy, sales, marketing, operations and market a…
Stated in 1 of 2 supplied quarters. Management reported: “Mr. Berrios brings more than 25 years of commercial leadership experience across the biopharmaceutical industry, with expertise spanning commercial strategy, sales, marketing, operations and market access.” “Most recently, he served as Head of U.S. Sales Strategy and Innovation for Obesity and Diabetes at Novo Nordisk and was instrumental in leading the strategic planning and commercial launch of its obesity and diabetes portfolio.”
“Mr. Berrios brings more than 25 years of commercial leadership experience across the biopharmaceutical industry, with expertise spanning commercial strategy, sales, marketing, operations and market a…”
Advance aleniglipron through Phase 3 ACCOMPLISH program with two clinical trials starting in second half of 2026 to support global regulatory submissions for chronic weight management.
Over the trailing year it converted 0.54x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, long-term interest rates, Fed net liquidity, real (inflation-adjusted) rates (low R² over the window).
7 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated neutral grew net income 46% of the time over the next year (vs 44% for the rest of the cohort, n=13229).
Not investment advice. As of 2026-11-05.